Cargando…
Optimizing T Cell-Based Therapy for Glioblastoma
Evading T cell surveillance is a hallmark of cancer. Patients with solid tissue malignancy, such as glioblastoma (GBM), have multiple forms of immune dysfunction, including defective T cell function. T cell dysfunction is exacerbated by standard treatment strategies such as steroids, chemotherapy, a...
Autores principales: | Karachi, Aida, Dastmalchi, Farhad, Nazarian, Saina, Huang, Jianping, Sayour, Elias J., Jin, Linchun, Yang, Changlin, Mitchell, Duane A., Rahman, Maryam |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8374079/ https://www.ncbi.nlm.nih.gov/pubmed/34421912 http://dx.doi.org/10.3389/fimmu.2021.705580 |
Ejemplares similares
-
The role of CMV in glioblastoma and implications for immunotherapeutic strategies
por: Rahman, Maryam, et al.
Publicado: (2018) -
Contemporary RNA Therapeutics for Glioblastoma
por: Melnick, Kaitlyn, et al.
Publicado: (2021) -
Sarcosine promotes trafficking of dendritic cells and improves efficacy of anti-tumor dendritic cell vaccines via CXC chemokine family signaling
por: Dastmalchi, Farhad, et al.
Publicado: (2019) -
Metabolomics Monitoring of Treatment Response to Brain Tumor Immunotherapy
por: Dastmalchi, Farhad, et al.
Publicado: (2021) -
The IDH1 Mutation-Induced Oncometabolite, 2-Hydroxyglutarate, May Affect DNA Methylation and Expression of PD-L1 in Gliomas
por: Mu, Luyan, et al.
Publicado: (2018)